Tag Archives: IntelGenx Technologies

H.C. Wainwright Reaffirms Their Buy Rating on IntelGenx Technologies (IGXT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on IntelGenx Technologies (IGXT – Research Report) today and set a price target of $1. The company’s shares closed on Friday at $0.41, close to its 52-week low of $0.39. According

Maxim Group Maintains Their Buy Rating on IntelGenx Technologies (IGXT)

Maxim Group analyst Jason McCarthy maintained a Buy rating on IntelGenx Technologies (IGXT – Research Report) yesterday and set a price target of $1.50. The company’s shares closed yesterday at $0.41, close to its 52-week low of $0.39. McCarthy observed:

Analysts Offer Insights on Healthcare Companies: IntelGenx Technologies (Other OTC: IGXT), Avrobio Inc (NASDAQ: AVRO) and Concert Pharma (NASDAQ: CNCE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IntelGenx Technologies (IGXT – Research Report), Avrobio Inc (AVRO – Research Report) and Concert Pharma (CNCE – Research Report) with bullish sentiments.

The EVP & CFO of IntelGenx Technologies (Other OTC: IGXT) is Buying Shares

Today, the EVP & CFO of IntelGenx Technologies (IGXT – Research Report), Andre Godin, bought shares of IGXT for $5,800. Following this transaction Andre Godin’s holding in the company was increased by 8.57% to a total of $73.61K. See today’s

H.C. Wainwright Thinks IntelGenx Technologies’ Stock is Going to Recover

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on IntelGenx Technologies (IGXT – Research Report), with a price target of $1.50. The company’s shares opened today at $0.61, close to its 52-week low of

Maxim Group Thinks IntelGenx Technologies’ Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on IntelGenx Technologies (IGXT – Research Report) today and set a price target of $2. The company’s shares closed yesterday at $0.60, close to its 52-week low of $0.55. McCarthy observed: